1/5/2023 10:36:27 PM
MediciNova To Meet With FDA To Discuss Clinical Development Of Parenteral Formulation Of MN-166
4/11/2022 6:37:42 AM
MediciNova Announces Plans For Phase 2 Trial Of MN-001 In NAFLD With Type 2 Diabetes Mellitus And Hypertriglyceridemia
2/1/2022 6:38:01 AM
MediciNova Gets New Patent Covering MN-001 For Hypertriglyceridemia, Hypercholesterolemia, Hyperlipoproteinemia In Korea
6/21/2021 6:35:33 AM
MediciNova Announces Positive Results From Phase 2 Trial Of MN-166 In Alcohol Use Disorder
3/28/2018 8:34:02 PM
B. Riley FBR Starts MediciNova Inc (MNOV) At Buy With $22 Price Target